Does the media prefer LFCR or SLDB?

In the previous week, Solid Biosciences had 14 more articles in the media than Lifecore Biomedical. MarketBeat recorded 16 mentions for Solid Biosciences and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.63 beat Solid Biosciences' score of 0.24 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LFCR or ZVRA?

In the previous week, Zevra Therapeutics had 10 more articles in the media than Lifecore Biomedical. MarketBeat recorded 12 mentions for Zevra Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.63 beat Zevra Therapeutics' score of 0.50 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLYM or LFCR?

In the previous week, Climb Bio had 5 more articles in the media than Lifecore Biomedical. MarketBeat recorded 7 mentions for Climb Bio and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.63 beat Climb Bio's score of 0.60 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lifecore Biomedical (LFCR) Competitors

$5.66 +0.09 (+1.62%)

Closing price 04:00 PM Eastern

Extended Trading

$5.66 +0.00 (+0.09%)

As of 07:09 PM Eastern

Compare

LFCR vs. RLMD, SLDB, ANRO, ZVRA, and CLYM

Should you buy Lifecore Biomedical stock or one of its competitors? MarketBeat compares Lifecore Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifecore Biomedical include Relmada Therapeutics (RLMD), Solid Biosciences (SLDB), Alto Neuroscience (ANRO), Zevra Therapeutics (ZVRA), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry.

How does Lifecore Biomedical compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Relmada Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Lifecore Biomedical has higher revenue and earnings than Relmada Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Lifecore Biomedical	$128.87M	1.65	-$35.26M	-$0.94	N/A

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Relmada Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Relmada Therapeutics' return on equity of -71.22% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

In the previous week, Lifecore Biomedical had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 2 mentions for Lifecore Biomedical and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.89 beat Lifecore Biomedical's score of 0.63 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relmada Therapeutics	Very Positive
Lifecore Biomedical	Positive

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 91.39%. Lifecore Biomedical has a consensus price target of $6.00, indicating a potential upside of 6.01%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Relmada Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Relmada Therapeutics and Lifecore Biomedical tied by winning 8 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Solid Biosciences?

Lifecore Biomedical (NASDAQ:LFCR) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Solid Biosciences' return on equity of -73.42% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Solid Biosciences	N/A	-73.42%	-61.13%

In the previous week, Solid Biosciences had 14 more articles in the media than Lifecore Biomedical. MarketBeat recorded 16 mentions for Solid Biosciences and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.63 beat Solid Biosciences' score of 0.24 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lifecore Biomedical has higher revenue and earnings than Solid Biosciences. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.65	-$35.26M	-$0.94	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Lifecore Biomedical presently has a consensus target price of $6.00, suggesting a potential upside of 6.01%. Solid Biosciences has a consensus target price of $17.00, suggesting a potential upside of 158.75%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Solid Biosciences beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Alto Neuroscience?

Lifecore Biomedical (NASDAQ:LFCR) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Lifecore Biomedical currently has a consensus target price of $6.00, suggesting a potential upside of 6.01%. Alto Neuroscience has a consensus target price of $35.25, suggesting a potential upside of 66.70%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Alto Neuroscience has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Alto Neuroscience's return on equity of -47.22% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Alto Neuroscience	N/A	-47.22%	-38.81%

In the previous week, Lifecore Biomedical had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 2 mentions for Lifecore Biomedical and 0 mentions for Alto Neuroscience. Lifecore Biomedical's average media sentiment score of 0.63 beat Alto Neuroscience's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Positive
Alto Neuroscience	Neutral

Lifecore Biomedical has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.65	-$35.26M	-$0.94	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

Lifecore Biomedical beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to Zevra Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Zevra Therapeutics had 10 more articles in the media than Lifecore Biomedical. MarketBeat recorded 12 mentions for Zevra Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.63 beat Zevra Therapeutics' score of 0.50 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has a net margin of 101.58% compared to Lifecore Biomedical's net margin of -25.43%. Zevra Therapeutics' return on equity of 51.49% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Zevra Therapeutics	101.58%	51.49%	28.86%

Zevra Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.65	-$35.26M	-$0.94	N/A
Zevra Therapeutics	$106.47M	7.59	$83.23M	$1.99	6.86

Lifecore Biomedical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Lifecore Biomedical currently has a consensus price target of $6.00, indicating a potential upside of 6.01%. Zevra Therapeutics has a consensus price target of $27.67, indicating a potential upside of 102.54%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Zevra Therapeutics beats Lifecore Biomedical on 11 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

In the previous week, Climb Bio had 5 more articles in the media than Lifecore Biomedical. MarketBeat recorded 7 mentions for Climb Bio and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.63 beat Climb Bio's score of 0.60 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Climb Bio's return on equity of -31.45% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

Lifecore Biomedical has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Lifecore Biomedical	$128.87M	1.65	-$35.26M	-$0.94	N/A

Climb Bio presently has a consensus target price of $21.64, suggesting a potential upside of 94.22%. Lifecore Biomedical has a consensus target price of $6.00, suggesting a potential upside of 6.01%. Given Climb Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Climb Bio is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Climb Bio and Lifecore Biomedical tied by winning 8 of the 16 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$208.93M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-6.02	18.68	24.75	23.76
Price / Sales	1.65	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	13.48	8.06	10.47	6.72
Net Income	-$35.26M	$23.83M	$3.56B	$337.35M
7 Day Performance	3.85%	-2.82%	-1.11%	-2.54%
1 Month Performance	18.16%	2.22%	1.28%	1.42%
1 Year Performance	-16.52%	37.70%	21.20%	24.71%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.0105 of 5 stars	$5.66 +1.6%	$6.00 +6.0%	-18.7%	$208.93M	$128.87M	N/A	690	Analyst Upgrade
RLMD Relmada Therapeutics	2.3429 of 5 stars	$6.42 -6.3%	$12.00 +86.9%	+585.1%	$718.50M	N/A	N/A	10	Positive News Gap Up High Trading Volume
SLDB Solid Biosciences	2.6047 of 5 stars	$6.58 -8.5%	$16.36 +148.7%	+41.2%	$707.85M	N/A	N/A	100
ANRO Alto Neuroscience	1.8771 of 5 stars	$18.76 -5.3%	$35.25 +87.9%	+610.2%	$694.86M	N/A	N/A	N/A
ZVRA Zevra Therapeutics	4.5264 of 5 stars	$10.88 -5.3%	$23.33 +114.5%	+30.6%	$679.23M	$106.47M	5.47	20	Trending News Analyst Downgrade Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. RLMD, SLDB, ANRO, ZVRA, and CLYM

How does Lifecore Biomedical compare to Relmada Therapeutics?

Summary

How does Lifecore Biomedical compare to Solid Biosciences?

Summary

How does Lifecore Biomedical compare to Alto Neuroscience?

Summary

How does Lifecore Biomedical compare to Zevra Therapeutics?

Summary

How does Lifecore Biomedical compare to Climb Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. RLMD, SLDB, ANRO, ZVRA, and CLYM

How does Lifecore Biomedical compare to Relmada Therapeutics?

Which has more volatility & risk, RLMD or LFCR?

Which has stronger earnings and valuation, RLMD or LFCR?

Do insiders & institutionals have more ownership in RLMD or LFCR?

Is RLMD or LFCR more profitable?

Does the media prefer RLMD or LFCR?

Do analysts prefer RLMD or LFCR?

Summary

How does Lifecore Biomedical compare to Solid Biosciences?

Which has more volatility & risk, LFCR or SLDB?

Is LFCR or SLDB more profitable?

Does the media prefer LFCR or SLDB?

Do institutionals & insiders hold more shares of LFCR or SLDB?

Which has better valuation and earnings, LFCR or SLDB?

Do analysts recommend LFCR or SLDB?

Summary

How does Lifecore Biomedical compare to Alto Neuroscience?

Do analysts recommend LFCR or ANRO?

Do insiders & institutionals hold more shares of LFCR or ANRO?

Which has more risk and volatility, LFCR or ANRO?

Is LFCR or ANRO more profitable?

Does the media prefer LFCR or ANRO?

Which has higher earnings & valuation, LFCR or ANRO?

Summary

How does Lifecore Biomedical compare to Zevra Therapeutics?

Does the media refer more to LFCR or ZVRA?

Is LFCR or ZVRA more profitable?

Which has higher valuation and earnings, LFCR or ZVRA?

Which has more volatility & risk, LFCR or ZVRA?

Do analysts recommend LFCR or ZVRA?

Do institutionals & insiders believe in LFCR or ZVRA?

Summary

How does Lifecore Biomedical compare to Climb Bio?

Which has more risk & volatility, CLYM or LFCR?

Does the media favor CLYM or LFCR?

Is CLYM or LFCR more profitable?

Which has preferable valuation & earnings, CLYM or LFCR?

Do analysts recommend CLYM or LFCR?

Do institutionals & insiders hold more shares of CLYM or LFCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools